Профилактика тромбоэмболических осложнений у лиц пожилого возраста с фибрилляцией предсердий

1. January CT, Wann LS, Alpert JS et al. 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation.
2. Российские клинические рекомендации «Диагностика и лечение фибрилляции предсердий», 2017.
3. Wang TJ, Larson MG, Lloyd-Jones DM et al. The lifetime risk of atrial fibrillation: the Framingham Heart Study [abstract]. Circulation 2002; 106 (2): 456.
4. Go AS, Hylek EM, Phillips KA et al. Prevalence of diagnosed atrial fibrillation in adults: JAMA 2001; 285 (18): 2370–5.
5. Wolf PA et al. Atrial fibrillation as an independent risk factor for stroke: The Framingham Study. Stroke 1991; 22: 983–8.
6. Gage BF, Waterman AD, Shannon W et al. Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA 2001; 285: 2864–70.
7. Olesen JB, Lip GY, Hansen ML et al. Validation of risk stratification schemes for predicting stroke and thromboembolism in patients with atrial fibrillation: nationwide cohort study. BMJ 2011; 342: d124.
8. Camm AJ, Kirchhof P, Lip GY et al. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J 2010; 31: 2369–429.
9. Ng KH, Hart RG, Eikelboom SW. Anticoagulation in Patiens Ages more 75 years with Atrial Fibrillation: Role of Novel Oral Anticoagulants. Cardiol Ther 2013; 2 (2): 135–49.
10. Friberg L, Rosenqvist M, Lip GY. Evaluation of risk stratification schemes for ischaemic stroke and bleeding in 182 678 patients with atrial fibrillation: the Swedish Atrial Fibrillation cohort study. Eur Heart J 2012; 33: 1500–10. 
11. Hijazi Z, Oldgren J, Lindback J et al. ARISTOTLE and RE‐LY Investigators. The novel biomarker‐based ABC (age, biomarkers, clinical history)‐bleeding risk score for patients with atrial fibrillation: a derivation and validation study. Lancet 2016; 387: 2302–11.
12. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J 2016; 37: 93–2962. 
13. Pisters R et al. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest 2010; 138: 1093–100.
14. Friberg L, Hammar N, Rosenqvist M. Stroke in paroxysmal atrialfibrillation: report from the Stockholm Cohort of Atrial Fibrillation. Circulation 2012; 125: 2298–307.
15. Pirmohamed M. Warfarin: almost 60 years old and still causing problems. Br J Clin Pharmacol 2006; 62: 509–11. 
16. Hirsh J et al. ACA/ACC Expert Consensus Document on Warfarin Therapy American Heart Association/American College of Cardiology Foundation Guide to Warfarin Therapy. JACC 2003; 41: 633–52.
17. Hart RG, Pearce LA, Aguilar MI. Metaanalysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med 2007; 146: 857–67.
18. Hirsh J et al. ACA/ACC Expert Consensus Document on Warfarin Therapy American Heart Association/American College of Cardiology Foundation Guide to Warfarin Therapy. JACC 2003; 41: 633–52. 
19. Schwarz UI, Ritchie MD, Bradford Y et al. Genetic determinants of response to warfarin during initial anticoagulation. N Engl J Med 2008; 358 (10): 999–1008.
20. Kakkar AK, Mueller I, Bassand JP et al. International longitudinal registry of patients with atrial fibrillation at risk of stroke: Global Anticoagulant Registry in the FIELD (GARFIELD). Am Heart J 2012; 163 (1): 13–9.
21. ACTIVE Writing Group; on behalf of the ACTIVE Investigators. Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial Fibrillation Clopidogrel Trial with Irbesartan for Prevention of Vascular Events (ACTIVE W): a randomized controlled trial. Lancet 2006; 367: 1903–12.
22. Turpie AG. Oral, direct factor Xa inhibitors in development for the prevention and treatment of thromboembolic diseases. Arterioscler Thromb Vasc Biol 2007; 27 (6): 1238–47.
23. Patel MR, Mahaffey KW, Garg J et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011; 365: 883–91.
24. Connolly S, Ezekowitz M, Yusuf S et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009; 361: 1139–51.
25. Granger CB et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011; 365 (11): 981–2.
26. Ruff CT, Giugliano RP, Braunwald E et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet 2014; 383: 955–62.
27. Hankey GJ, Patel MR, Stevens SR et al; ROCKET AF Steering Committee Investigators. Rivaroxaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a subgroup analysis of ROCKET AF. Lancet Neurol 2012; 11: 315–22.
28. Fox KA, Piccini JP, Wojdyla D et al. Prevention of stroke and systemic embolism with rivaroxaban compared with warfarin in patients with non-valvular atrial fibrillation and moderate renal impairment. Eur Heart J 2011; 32 (19): 2387–94.
29. Halperin JL, Hankey GJ, Wojdyla DM et al. (ROCKET AF Steering Committee and Investigators, 2014.). Efficacy and Safety of Rivaroxaban Compared With Warfarin Among Elderly Patients With Nonvalvular Atrial Fibrillation in the Rivaroxaban Once Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF). Circulation 2014; 8 (130): 138–46.
30. Halvorsen S, Atar D, Yang H et al. Efficacy and safety of apixaban compared with warfarin according to age for stroke prevention in atrial fibrillation: observations from the ARISTOTLE trial. Eur Heart J 2014; 35 (28): 1864–72. 
31. Eikelboom JW, Wallentin L, Connolly SJ et al. Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial. Circulation 2011; 123: 2363–72.
32. Бойцов С.А., Лукьянов М.М., Якушин С.С. Регистр кардиоваскулярных заболеваний (РЕКВАЗА): диагностика, сочетанная сердечно-сосудистая патология, сопутствующие заболевания и лечение в условиях реальной амбулаторно-поликлинической практики. Кардиоваск. терапия и профилактика. 2014; 13 (6): 44–50.
33. Беленков Ю.Н., Шакарьянц Г.А., Хабарова Н.В., Ан Г. Антикоагулянтная терапия у пожилых пациентов с фибрилляцией предсердий. Кардиология. 2018; 58 (10): 44–51.
34. Olesen JB, Lip GY, Kamper AL et al. Stroke and bleeding in atrial fibrillation with chronic kidney disease. N Engl J Med 2012; 367 (7): 625–35.
35. Coleman CI, Weeda ER, Nguyen E et al. Effectiveness and Safety of Rivaroxaban Versus Warfarin in Patients 80+ Years of Age with Nonvalvular Atrial Fibrillation. Abstract S3173 presented at the 2017 Scientific Sessions of the American Heart Association (AHA), 11–15 November 2017, Anaheim, CA, USA.
36. Sharma M, Cornelius VR, Patel JP et al. Efficacy and Harms of Direct Oral Anticoagulants in the Elderly for Stroke Prevention in Atrial Fibrillation and Secondary Prevention of Venous Thromboembolism: Systematic Review and Meta-Analysis. Circulation 2015; 132 (3): 194–204.
37. Chao TF, Liu CJ, Lin YJ et al. Oral anticoagulation in very elderly patients with atrial fibrillation – a nationwide cohort study. Circulation 2018; 138 (1): 37–47.
38. Fauchier L, Blin P, Sacher F et al. Effectiveness and Safety of Rivaroxaban 15 mg Compared with Vitamin K Antagonists in Very Elderly Patients with Atrial Fibrillation. 
Abstract 20559 presented at the 2017 Scientific Sessions of the American Heart Association (AHA), 11–15 November 2017, Anaheim, CA, USA.
39. Yao X, Shah ND, Sangaralingham LR et al. Non-Vitamin K Antagonist Oral Anticoagulant Dosing in Patients With Atrial Fibrillation and Renal Dysfunction. J Am Coll Cardiol 2017; 69: 2779–90.
40. Nielsen PB, Skjøth F, Søgaard M et al. Effectiveness and safety of reduced dose non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study. BMJ 2017; 356: j510.
41. Zamorano JL, Greiner W, Sandberg A et al. Patient preferences for chronic treatment for stroke prevention: results from the European Patients survey in Atrial Fibrillation (EUPS-AF). Annual Congress of the European Society of Cardiology, Munich, 2012.
42. Coleman CI, Roberts MS, Sobieraj DM et al. Effect of dosing frequency on chronic cardiovascular disease medication adherence. Curr Med Res Opin 2012; 28 (5): 669–80.
43. Diamantopoulos А, Forster F, Evers T. Real-life treatment persistence with newer oral anticoagulants and potential strokes avoided in patients with atrial fibrillation. ESC Congress 2013, poster P519.
44. Camm AJ, Amarenco P, Haas S et al. XANTUS: a real-world, prospective, observational study of patients treated with rivaroxaban for stroke prevention in atrial fibrillation. Eur Heart J 2016; 37 (14): 1145–53.
45. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke 1991; 22: 983–8.
46. Olesen JB et al. BMJ 2011; 342: d124.
47. Camm AJ et al. Eur Heart J 2010; 31: 2369–429.
48. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J 2016; 37: 93–2962.
49. Halperin J et al. Circulation 2014; 130: 138–46.
50. Patel MR et al. 2011.
51. Connolly SJ et al. 2009. 
52. Granger CB et al. 2011. 
53. Hankey GJ et al. Lancet Neurol 2012; 11 (4): 315–22.
54. Diener H-C et al. Lancet Neurol 2010; 9: 1157–63.
55. Еaston JD et al. Lancet Neurol 2012; 11 (6): 503–11.
56. Eikelboom JW et al. Circulation 2011; 123: 2363–72.
57. Halperin JL et al. Circulation 2014; 130: 138–46.
58. Olesen JB. Stroke and Bleeding in Atrial Fibrillation with Chronic Kidney Disease. N Engl J Med 2012; 367 (7): 625–36.
59. Sharma M et al. Circulation 2015; 132 (3): 194–204.
60. Nielsen PB et al. BMJ 2017 Feb 10; 356: j510. DOI: 10.1136/bmj.j510
61. Инструкция по применению лекарственного препарата для медицинского применения Ксарелто® 15/20 мг ЛП-001457. Актуальная версия инструкции от 03.07.2019.

Г.А. Барышникова, С.А. Чорбинская, Д.В. Привалов, И.И. Степанова